Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma

A rospective study

Kouichi Isobe, Hiroyuki Kawakami, Jun Ichi Tamaru, Shigeo Yasuda, Takashi Uno, Takashi Aruga, Tetsuya Kawata, Naoyuki Shigematsu, Kazuo Hatano, Toshiyuki Takagi, Atsuo Mikata, Hisao Ito

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Many physicians administer involved field radiation therapy (RT) following brief chemotherapy for localized aggressive non-Hodgkin's lymphoma. Involved field irradiation usually implies treatment to the involved nodal regions with and without the contiguous lymphatic region, however, there is no agreements about its definition. Here we assess the appropriateness of RT irrespective of lymph node regions (localized field) following chemotherapy for patients with early stage diffuse large B-cell lymphoma. The localized field encompassed all original gross tumor volumes before chemotherapy with at least a 2- to 3-cm margin irrespective of lymphatic regions. We also evaluated the suitable radiation dose on the basis of response to chemotherapy. Twenty five eligible patients were treated with 3 cycles of chemotherapy (CHOP) followed by RT. All 25 patients had disease confined to Waldeyer's ring and/or cervical lymph nodes. Twenty two patients in complete response following chemotherapy received 30 Gy, and the remaining 3 in partial response received 40 Gy. With a median follow up of 42 months, both event free and overall survival rates at 2 years were 96.0%. There were no in-field recurrences, however, two patients experienced relapses. One developed central nervous system involvement and subsequently died of his disease. The other had mediastinal and submental lymph node relapse at 32 months, and is alive after salvage chemotherapy. Our study demonstrated that it should be possible to reduce treatment volume to less than the conventional involved field, and to limit the dose of RT in the range of 30-40Gy.

Original languageEnglish
Pages (from-to)1535-1539
Number of pages5
JournalLeukemia and Lymphoma
Volume44
Issue number9
DOIs
Publication statusPublished - 2003 Sep 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Radiotherapy
Drug Therapy
Lymph Nodes
Recurrence
Tumor Burden
Non-Hodgkin's Lymphoma
Disease-Free Survival
Survival Rate
Central Nervous System
Radiation
Physicians
Therapeutics

Keywords

  • Brief chemotherapy
  • Diffuse large B-cell lymphoma
  • Involved field
  • Localized field
  • Total dose

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma : A rospective study. / Isobe, Kouichi; Kawakami, Hiroyuki; Tamaru, Jun Ichi; Yasuda, Shigeo; Uno, Takashi; Aruga, Takashi; Kawata, Tetsuya; Shigematsu, Naoyuki; Hatano, Kazuo; Takagi, Toshiyuki; Mikata, Atsuo; Ito, Hisao.

In: Leukemia and Lymphoma, Vol. 44, No. 9, 01.09.2003, p. 1535-1539.

Research output: Contribution to journalArticle

Isobe, K, Kawakami, H, Tamaru, JI, Yasuda, S, Uno, T, Aruga, T, Kawata, T, Shigematsu, N, Hatano, K, Takagi, T, Mikata, A & Ito, H 2003, 'Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: A rospective study', Leukemia and Lymphoma, vol. 44, no. 9, pp. 1535-1539. https://doi.org/10.1080/1042819031000097357
Isobe, Kouichi ; Kawakami, Hiroyuki ; Tamaru, Jun Ichi ; Yasuda, Shigeo ; Uno, Takashi ; Aruga, Takashi ; Kawata, Tetsuya ; Shigematsu, Naoyuki ; Hatano, Kazuo ; Takagi, Toshiyuki ; Mikata, Atsuo ; Ito, Hisao. / Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma : A rospective study. In: Leukemia and Lymphoma. 2003 ; Vol. 44, No. 9. pp. 1535-1539.
@article{e4c9e255c9054b80a1415516a4bd6997,
title = "Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: A rospective study",
abstract = "Many physicians administer involved field radiation therapy (RT) following brief chemotherapy for localized aggressive non-Hodgkin's lymphoma. Involved field irradiation usually implies treatment to the involved nodal regions with and without the contiguous lymphatic region, however, there is no agreements about its definition. Here we assess the appropriateness of RT irrespective of lymph node regions (localized field) following chemotherapy for patients with early stage diffuse large B-cell lymphoma. The localized field encompassed all original gross tumor volumes before chemotherapy with at least a 2- to 3-cm margin irrespective of lymphatic regions. We also evaluated the suitable radiation dose on the basis of response to chemotherapy. Twenty five eligible patients were treated with 3 cycles of chemotherapy (CHOP) followed by RT. All 25 patients had disease confined to Waldeyer's ring and/or cervical lymph nodes. Twenty two patients in complete response following chemotherapy received 30 Gy, and the remaining 3 in partial response received 40 Gy. With a median follow up of 42 months, both event free and overall survival rates at 2 years were 96.0{\%}. There were no in-field recurrences, however, two patients experienced relapses. One developed central nervous system involvement and subsequently died of his disease. The other had mediastinal and submental lymph node relapse at 32 months, and is alive after salvage chemotherapy. Our study demonstrated that it should be possible to reduce treatment volume to less than the conventional involved field, and to limit the dose of RT in the range of 30-40Gy.",
keywords = "Brief chemotherapy, Diffuse large B-cell lymphoma, Involved field, Localized field, Total dose",
author = "Kouichi Isobe and Hiroyuki Kawakami and Tamaru, {Jun Ichi} and Shigeo Yasuda and Takashi Uno and Takashi Aruga and Tetsuya Kawata and Naoyuki Shigematsu and Kazuo Hatano and Toshiyuki Takagi and Atsuo Mikata and Hisao Ito",
year = "2003",
month = "9",
day = "1",
doi = "10.1080/1042819031000097357",
language = "English",
volume = "44",
pages = "1535--1539",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma

T2 - A rospective study

AU - Isobe, Kouichi

AU - Kawakami, Hiroyuki

AU - Tamaru, Jun Ichi

AU - Yasuda, Shigeo

AU - Uno, Takashi

AU - Aruga, Takashi

AU - Kawata, Tetsuya

AU - Shigematsu, Naoyuki

AU - Hatano, Kazuo

AU - Takagi, Toshiyuki

AU - Mikata, Atsuo

AU - Ito, Hisao

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Many physicians administer involved field radiation therapy (RT) following brief chemotherapy for localized aggressive non-Hodgkin's lymphoma. Involved field irradiation usually implies treatment to the involved nodal regions with and without the contiguous lymphatic region, however, there is no agreements about its definition. Here we assess the appropriateness of RT irrespective of lymph node regions (localized field) following chemotherapy for patients with early stage diffuse large B-cell lymphoma. The localized field encompassed all original gross tumor volumes before chemotherapy with at least a 2- to 3-cm margin irrespective of lymphatic regions. We also evaluated the suitable radiation dose on the basis of response to chemotherapy. Twenty five eligible patients were treated with 3 cycles of chemotherapy (CHOP) followed by RT. All 25 patients had disease confined to Waldeyer's ring and/or cervical lymph nodes. Twenty two patients in complete response following chemotherapy received 30 Gy, and the remaining 3 in partial response received 40 Gy. With a median follow up of 42 months, both event free and overall survival rates at 2 years were 96.0%. There were no in-field recurrences, however, two patients experienced relapses. One developed central nervous system involvement and subsequently died of his disease. The other had mediastinal and submental lymph node relapse at 32 months, and is alive after salvage chemotherapy. Our study demonstrated that it should be possible to reduce treatment volume to less than the conventional involved field, and to limit the dose of RT in the range of 30-40Gy.

AB - Many physicians administer involved field radiation therapy (RT) following brief chemotherapy for localized aggressive non-Hodgkin's lymphoma. Involved field irradiation usually implies treatment to the involved nodal regions with and without the contiguous lymphatic region, however, there is no agreements about its definition. Here we assess the appropriateness of RT irrespective of lymph node regions (localized field) following chemotherapy for patients with early stage diffuse large B-cell lymphoma. The localized field encompassed all original gross tumor volumes before chemotherapy with at least a 2- to 3-cm margin irrespective of lymphatic regions. We also evaluated the suitable radiation dose on the basis of response to chemotherapy. Twenty five eligible patients were treated with 3 cycles of chemotherapy (CHOP) followed by RT. All 25 patients had disease confined to Waldeyer's ring and/or cervical lymph nodes. Twenty two patients in complete response following chemotherapy received 30 Gy, and the remaining 3 in partial response received 40 Gy. With a median follow up of 42 months, both event free and overall survival rates at 2 years were 96.0%. There were no in-field recurrences, however, two patients experienced relapses. One developed central nervous system involvement and subsequently died of his disease. The other had mediastinal and submental lymph node relapse at 32 months, and is alive after salvage chemotherapy. Our study demonstrated that it should be possible to reduce treatment volume to less than the conventional involved field, and to limit the dose of RT in the range of 30-40Gy.

KW - Brief chemotherapy

KW - Diffuse large B-cell lymphoma

KW - Involved field

KW - Localized field

KW - Total dose

UR - http://www.scopus.com/inward/record.url?scp=10744225151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744225151&partnerID=8YFLogxK

U2 - 10.1080/1042819031000097357

DO - 10.1080/1042819031000097357

M3 - Article

VL - 44

SP - 1535

EP - 1539

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -